LEARN MORE ABOUT sAML
WITH OUR VIDEO LIBRARY
Watch these videos to hear Dr. Jonathan Abbas, Director of the Acute Leukemia and Blood Cancer Program at Tennessee Oncology, discuss challenges in sAML subtypes, including t-AML and AML-MRC.
Video Duration: 3:40
Distinct Features of sAML Subtypes
It is important to properly identify patients with sAML and consider a treatment plan with curative intent for appropriate patients. In this video, Dr. Abbas reviews the definition of t-AML and AML-MRC and discusses some of the high-risk features of these sAML subtypes.
Video Duration: 2:37
sAML Risk Factors
It is important for patients with MDS to be proactively and routinely monitored for progression to secondary AML. In this video, Dr. Abbas outlines risk factors associated with disease progression from MDS to AML-MRC and some approaches to monitor these patients for sAML disease progression.
Video Duration: 2:48
sAML Management Challenges
Patients with sAML have historically exhibited poor survival. In this video, Dr. Abbas examines challenges in managing sAML and highlights treatment approaches to consider for optimizing sAML patient outcomes.
Video Duration: 1:36
sAML Patient Considerations
Intensive chemotherapy may not be the right choice for every patient with sAML, but it is important to identify those sAML patients who would benefit from this therapy. In this video, Dr. Abbas discusses factors to consider when deciding if a patient is an appropriate candidate for intensive therapy.